Real‐World Effectiveness and 12‐Month Persistence of a Semaglutide‐Supported Digital Weight‐Loss Service: A Retrospective Cohort Study in Germany
Authors' conclusion
The population-level impact of this DWLS is fundamentally limited by high attrition (88%) in an unsubsidised environment. While significant weight loss is possible for a non-representative adherent minority, the mean effectiveness for the total initiating population (2.40% WCS) highlights that real-world success is strictly conditional upon long-term persistence.
Study context
- Population
- Patients initiating a semaglutide-supported digital weight-loss service (Juniper Germany), real-world German cohort
- Participants
- 4,535 vs 546
- Exposure
- Total vs Adherent sub-cohort
- Totaln = 4,535
- Adherent sub-cohortn = 546
- Outcome
- 12-month medication and data submission adherence (receiving ≥ 10 orders) and mean weight-loss percentage
- Follow-up
- 12 months
Methodological detailsreal-world, per-protocol and intention-to-treat analyses, Last Observation Carried Forward (LOCF), worst-case scenario sensitivity model
- Real-world
- Per-protocol and intention-to-treat analyses
- LOCF
- Worst-case scenario sensitivity model
Main finding
As reported in the abstract
Mean weight loss
| Group | Value | Proportion adherent |
|---|---|---|
| Total | mean 9.47 % | |
| Adherent sub-cohort | mean 15.13 ± 7.1 % | 12% |
Value
Totalmean 9.47 %
Adherent sub-cohortmean 15.13 ± 7.1 %
Proportion adherent
Total— not stated in the abstract
Adherent sub-cohort12%
- Mean weight loss, total cohort, Worst-Case Scenario (WCS) sensitivity model (0% weight loss assumed for all dropouts)
- 2.40%
Observational data: associations, not effects.
Further findings
Predictors of churn (attrition)
- Achieving healthy BMI milestone
- OR = 0.29, p < 0.001
- Weight-loss plateau
- OR = 0.41, p < 0.001
- Higher baseline obesity severity (Obesity Class I-III), greater persistence
- P < 0.023
- ≥ 3 comorbidities
- OR = 2.12, p = 0.002
- Previous GLP-1 RA use
- OR = 1.57, p = 0.001
- Moderate early engagement (2-10 logs), predictor of persistence
- P < 0.001
- Intensive tracking (> 10 logs), no significant reduction in churn
- P = 0.393
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Real‐World Effectiveness and 12‐Month Persistence of a Semaglutide‐Supported Digital Weight‐Loss Service: A Retrospective Cohort Study in Germany. Diabetes Obes Metab. Published 25 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →